JP2023533273A - Oral composition for improving bad breath - Google Patents
Oral composition for improving bad breath Download PDFInfo
- Publication number
- JP2023533273A JP2023533273A JP2023500348A JP2023500348A JP2023533273A JP 2023533273 A JP2023533273 A JP 2023533273A JP 2023500348 A JP2023500348 A JP 2023500348A JP 2023500348 A JP2023500348 A JP 2023500348A JP 2023533273 A JP2023533273 A JP 2023533273A
- Authority
- JP
- Japan
- Prior art keywords
- halitosis
- improving
- bad breath
- oral
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010006326 Breath odour Diseases 0.000 title claims abstract description 132
- 239000000203 mixture Substances 0.000 title claims abstract description 100
- 229920001661 Chitosan Polymers 0.000 claims abstract description 72
- 208000032139 Halitosis Diseases 0.000 claims abstract description 70
- 229940094952 green tea extract Drugs 0.000 claims abstract description 70
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 70
- 210000000214 mouth Anatomy 0.000 claims abstract description 47
- 239000004480 active ingredient Substances 0.000 claims abstract description 25
- 239000002904 solvent Substances 0.000 claims abstract description 25
- -1 dimethyl mercaptan Chemical compound 0.000 claims abstract description 18
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 16
- 239000004615 ingredient Substances 0.000 claims abstract description 15
- 239000000796 flavoring agent Substances 0.000 claims abstract description 10
- 239000003002 pH adjusting agent Substances 0.000 claims abstract description 8
- 229920000642 polymer Polymers 0.000 claims abstract description 7
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 6
- 239000003755 preservative agent Substances 0.000 claims abstract description 6
- 239000003765 sweetening agent Substances 0.000 claims abstract description 6
- 229920005862 polyol Polymers 0.000 claims abstract description 5
- 150000003077 polyols Chemical class 0.000 claims abstract description 5
- 239000003899 bactericide agent Substances 0.000 claims abstract description 4
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 33
- 235000005487 catechin Nutrition 0.000 claims description 33
- 150000001765 catechin Chemical class 0.000 claims description 26
- 208000024693 gingival disease Diseases 0.000 claims description 7
- 230000002421 anti-septic effect Effects 0.000 claims description 4
- 239000000049 pigment Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 3
- 239000002304 perfume Substances 0.000 claims 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 abstract description 14
- 235000019629 palatability Nutrition 0.000 abstract description 13
- 208000002925 dental caries Diseases 0.000 abstract description 8
- 150000003568 thioethers Chemical class 0.000 abstract description 8
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 abstract description 7
- 235000013355 food flavoring agent Nutrition 0.000 abstract description 7
- 229910000037 hydrogen sulfide Inorganic materials 0.000 abstract description 6
- 239000003112 inhibitor Substances 0.000 abstract description 4
- 239000003205 fragrance Substances 0.000 abstract description 3
- 239000000975 dye Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 34
- 239000000284 extract Substances 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 18
- 238000000605 extraction Methods 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000002699 waste material Substances 0.000 description 12
- 235000019606 astringent taste Nutrition 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000001569 carbon dioxide Substances 0.000 description 9
- 229910002092 carbon dioxide Inorganic materials 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000002324 mouth wash Substances 0.000 description 8
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 7
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 7
- 240000003553 Leptospermum scoparium Species 0.000 description 7
- 235000015459 Lycium barbarum Nutrition 0.000 description 7
- 208000025157 Oral disease Diseases 0.000 description 7
- 229950001002 cianidanol Drugs 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 208000030194 mouth disease Diseases 0.000 description 7
- 229940051866 mouthwash Drugs 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000000194 supercritical-fluid extraction Methods 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 239000000606 toothpaste Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 239000002280 amphoteric surfactant Substances 0.000 description 4
- 239000003945 anionic surfactant Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000002137 ultrasound extraction Methods 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 235000006468 Thea sinensis Nutrition 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000002554 disease preventive effect Effects 0.000 description 3
- 235000019820 disodium diphosphate Nutrition 0.000 description 3
- GYQBBRRVRKFJRG-UHFFFAOYSA-L disodium pyrophosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 239000002075 main ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 235000019832 sodium triphosphate Nutrition 0.000 description 3
- 229940092665 tea leaf extract Drugs 0.000 description 3
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 208000006558 Dental Calculus Diseases 0.000 description 2
- 208000002064 Dental Plaque Diseases 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 229920000388 Polyphosphate Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 241000241413 Propolis Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960005233 cineole Drugs 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- JOZKFWLRHCDGJA-UHFFFAOYSA-N citronellol acetate Chemical compound CC(=O)OCCC(C)CCC=C(C)C JOZKFWLRHCDGJA-UHFFFAOYSA-N 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000850 deacetylating effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 229940069949 propolis Drugs 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 2
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 229940104261 taurate Drugs 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- NOOLISFMXDJSKH-ZDGBYWQASA-N (2s,5r)-5-methyl-2-propan-2-ylcyclohexan-1-ol Chemical compound CC(C)[C@@H]1CC[C@@H](C)CC1O NOOLISFMXDJSKH-ZDGBYWQASA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- KRLBLPBPZSSIGH-CSKARUKUSA-N (6e)-3,7-dimethylnona-1,6-dien-3-ol Chemical compound CC\C(C)=C\CCC(C)(O)C=C KRLBLPBPZSSIGH-CSKARUKUSA-N 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- CLWAXFZCVYJLLM-UHFFFAOYSA-N 1-chlorohexadecane Chemical compound CCCCCCCCCCCCCCCCCl CLWAXFZCVYJLLM-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 241000332371 Abutilon x hybridum Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 240000008025 Alternanthera ficoidea Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- JOZKFWLRHCDGJA-LLVKDONJSA-N Citronellyl acetate Natural products CC(=O)OCC[C@H](C)CCC=C(C)C JOZKFWLRHCDGJA-LLVKDONJSA-N 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 206010031009 Oral pain Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 241000920652 Quercus lusitanica Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229930007050 cineol Natural products 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 239000002442 collagenase inhibitor Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 108010046301 glucose peroxidase Proteins 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 150000007823 ocimene derivatives Chemical class 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000020737 peppermint extract Nutrition 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 229940112950 sage extract Drugs 0.000 description 1
- 235000020752 sage extract Nutrition 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000012420 sanguinaria Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- XJPBRODHZKDRCB-UHFFFAOYSA-N trans-alpha-ocimene Natural products CC(=C)CCC=C(C)C=C XJPBRODHZKDRCB-UHFFFAOYSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
本発明は、口臭改善用口腔組成物であり、口臭の原因となる硫化水素、メチルメルカプタン及びジメチルメルカプタンなどの揮発性硫化物を除去するために、前記揮発性硫化物を発生させるタンパク質老廃物の分解成分を効果的に除去できる口腔組成物に関する。具体的に本発明は、キトサン及び緑茶抽出物を有効成分として含む口臭改善用口腔組成物であり、前記口臭改善用口腔組成物は、ポリオール、ポリマー、殺菌剤、う蝕抑制剤、口臭除去有効成分、pH調節剤、保存剤、防腐剤、着香剤、甘味剤、香料、色素及び溶剤からなる群から選択された1種以上の追加成分をさらに含むことができる。前記本発明の口臭改善用口腔組成物は、効果的な口臭除去を通じて口臭を改善し、嗜好度に優れて使用感もとてもいい。
The present invention is an oral cavity composition for improving bad breath, and is used to remove volatile sulfides such as hydrogen sulfide, methyl mercaptan, and dimethyl mercaptan that cause bad breath. The present invention relates to an oral composition capable of effectively removing decomposed components. Specifically, the present invention is an oral composition for improving halitosis containing chitosan and a green tea extract as active ingredients, and the oral composition for improving halitosis comprises a polyol, a polymer, a bactericide, a caries inhibitor, and an effective oral malodor remover. It can further comprise one or more additional ingredients selected from the group consisting of ingredients, pH adjusting agents, preservatives, preservatives, flavoring agents, sweetening agents, fragrances, dyes and solvents. The oral composition for improving halitosis of the present invention improves halitosis by effectively removing halitosis, has excellent palatability, and feels very good when used.
Description
本発明は、口腔組成物、具体的には口臭成分を除去して口臭を改善することができる口臭改善用口腔組成物に関する。 TECHNICAL FIELD The present invention relates to an oral composition, specifically an oral composition for improving halitosis that can remove halitosis components to improve halitosis.
現代社会においては、産業化及び西欧化に伴い、生活習慣や食生活の変化により口腔関連疾患の原因と症状が多様化しており、口腔の関連疾患及び関連問題は深刻な社会問題として報告されている。 In modern society, along with industrialization and westernization, the causes and symptoms of oral-related diseases are diversifying due to changes in lifestyle and dietary habits, and oral-related diseases and related problems have been reported as serious social problems. there is
口腔は呼吸と食物摂取を行う上で非常に重要な器官であるが、空気と食物を通じて絶えず外部の環境にさらされる器官でもある。そのため、歯磨きで口腔の清潔さを保たないと、歯と歯茎の周りに歯垢と歯石が発生して、様々な病気を引き起こす可能性がある。 The oral cavity is a very important organ for respiration and food intake, but it is also an organ that is constantly exposed to the external environment through air and food. Therefore, if you do not keep your oral cavity clean by brushing your teeth, plaque and tartar will form around your teeth and gums, which can lead to various diseases.
世界保健機関(WHO)では、う蝕、歯周疾患、口臭及び口腔痛などの口腔疾患を、未来に解決すべき主要な保健問題の一つとして認識しており、世界保健機関の歯科疾患に関する報告によると、世界的に、青少年の60~90%と成人の60%がう蝕と歯周疾患を患っており、35歳~44歳の中年成人の15~20%は重度の歯周疾患を有している。このような口腔関連疾患は、歯の損失の主な原因となるだけでなく、心血管系疾患、細菌性肺炎、低体重出生児、糖尿合併症や骨粗鬆症などの病気の潜在的な危険要因となると報告されている。 The World Health Organization (WHO) recognizes oral diseases such as dental caries, periodontal disease, bad breath and oral pain as one of the major health problems to be solved in the future. Globally, 60-90% of adolescents and 60% of adults have caries and periodontal disease, and 15-20% of middle-aged adults aged 35-44 years have severe periodontal disease. have a disease. Such oral diseases are not only the leading cause of tooth loss, but also a potential risk factor for diseases such as cardiovascular disease, bacterial pneumonia, low birth weight, diabetes complications and osteoporosis. It is reported that
前記のように、空気と食物を通じて絶えず外部の環境にさらされる器官である人の口腔は、湿度が高く体温が安定的に保たれて、食物が腐りやすく細菌が繁殖するのに格好の環境である。人の口腔内には700種以上の様々な菌が常在しており、口腔内の細菌は常在菌と病原菌で構成されている。常在菌は病原菌の繁殖を防いで口腔の健康を保たせてくれるのに対し、口腔疾患を引き起こす細菌はほとんどが歯と歯茎の間に形成される細菌膜である歯垢(プラーク)に存在することが知られている。病原菌は歯垢(プラーク)から毒素や酸を産生し、病原菌が産生した毒素は歯周組織内に侵入して歯齦の炎症、歯槽骨の破壊及び感染を起こし、病原菌によって産生された酸は歯の表面を溶かしてう蝕症の原因となり、口臭を誘発する原因として作用することもある。 As mentioned above, the human oral cavity, which is an organ that is constantly exposed to the external environment through air and food, is highly humid and maintains a stable body temperature, making it an ideal environment for food to spoil and for bacteria to proliferate. be. More than 700 species of various bacteria are resident in the human oral cavity, and the bacteria in the oral cavity are composed of resident bacteria and pathogenic bacteria. Indigenous bacteria prevent the growth of pathogenic bacteria and maintain oral health, whereas most of the bacteria that cause oral diseases are present in dental plaque, which is a bacterial film formed between teeth and gums. known to do. Pathogenic bacteria produce toxins and acids from dental plaque (plaque), the toxins produced by pathogenic bacteria enter the periodontal tissue and cause inflammation of the gums, destruction and infection of the alveolar bone, and the acid produced by the pathogenic bacteria causes tooth decay. It dissolves the surface of the tooth and causes dental caries, and may also act as a cause of bad breath.
前記口臭誘発に関連して、社会発展に伴う対人関係の範囲及び活動の増加、衛生概念の発達に伴い、口臭に対する認識が次第に高まっており、これにより口臭を積極的にケアしようとする消費者がますます増加する傾向にある。このような変化に合わせて口臭除去に効果的な施術を行ったり、薬剤を歯磨き粉、うがい液、カプセル、付着剤などに配合するなど、国内外で様々な研究が行われてきた。 In relation to halitosis induction, with the increase in the range of interpersonal relationships and activities accompanying social development and the development of hygiene concepts, awareness of halitosis is gradually increasing, and consumers actively try to care for halitosis. tend to increase more and more. In response to these changes, various studies have been conducted both in Japan and overseas, such as performing effective treatments to remove bad breath and adding drugs to toothpaste, mouthwash, capsules, adhesives, etc.
口臭の原因は、口腔内原因と口腔外原因の二つに大きく分類することができ、口腔内原因としては、代表的に口腔内の微生物又は未治療のう蝕症、歯周疾患などの口腔疾患が挙げられ、口腔外原因としては、呼吸器系疾患、胃腸系疾患などと、空腹、月経、喫煙、飲酒などの様々な原因が挙げられる。 Causes of halitosis can be broadly classified into two: intraoral causes and extraoral causes. Diseases can be mentioned, and extraoral causes include respiratory diseases, gastrointestinal diseases, etc., and various causes such as hunger, menstruation, smoking and drinking.
前記原因の中でも主な原因である口腔内原因による口臭は、口腔内の酵素が唾液中に存在する食べかす、微生物、口腔上皮、脱着された口腔粘膜や結合組織などをタンパク質源とし、これらを分解することにより揮発性硫化物を産生して発生することが知られている。前記口臭を引き起こす主成分である揮発性硫化物には、硫化水素、メチルメルカプタン及びジメチルメルカプタンなどがあり、これらの揮発性硫化物の他に、トリエチルアミンなどの揮発性アミン化合物、アルデヒド、脂肪酸及びアンモニアなどがある。 Halitosis caused by oral causation, which is the main cause among the above-mentioned causes, is caused by enzymes in the oral cavity that use food debris present in saliva, microorganisms, oral epithelium, desorbed oral mucosa and connective tissue as protein sources, and decompose these. It is known that volatile sulfides are generated by Volatile sulfides, which are the main components causing bad breath, include hydrogen sulfide, methyl mercaptan and dimethyl mercaptan. and so on.
従来の口臭除去関連技術を見てみると、主に口臭を引き起こす原因菌に対する抗菌剤及び口臭原因物質に対するマスキング成分を含む歯磨き粉とうがい液に関する研究が行われてきた。しかし、これらの製剤は口臭除去効果を発現し維持するのには使用上の制約が幾つかある。例えば、歯磨き粉の場合、歯を磨いた後は効能成分を維持することができないという短所がある。このような短所を補うために、ポリマーを適用して薬物の送達効果を増大しようとする試みが行われてきたが、従来の歯磨き粉のような軟膏状剤形を使用するためには歯ブラシを用いて歯を磨かなければならず、また水で口をすすがなければならないので、場所に制約があるという短所が依然として残っている。この他に、マウススプレーやブレスフィルムなどの剤形に関わる研究も行われた。しかし、マウススプレーやブレスフィルムの場合、効能の持続時間が短くて効能体感に限界があるという問題点があり、特に、ブレスフィルムの場合は、温度や湿度などにより、製造されたフィルムの収縮や凝集などの現象が発生して流通上の問題点もさらに加わる。 Looking at conventional technologies related to halitosis removal, research has mainly been conducted on toothpastes and mouthwashes containing antibacterial agents against halitosis-causing bacteria and masking ingredients against halitosis-causing substances. However, these preparations have some restrictions in use in order to develop and maintain the breath-removing effect. For example, toothpaste has the disadvantage that it cannot maintain the effective ingredients after brushing the teeth. Attempts have been made to increase the drug delivery effect by applying polymers to compensate for these shortcomings. The disadvantage of limited space still remains because one must brush one's teeth and rinse one's mouth with water. In addition, research was conducted on formulations such as mouth sprays and breath films. However, in the case of mouth sprays and breath films, there is a problem that the duration of effect is short and the experience of efficacy is limited. Phenomena such as agglomeration occur, and problems in distribution are further added.
この他に、口腔内で発生する口臭を抑制するために、口歯を引き起こす物質、一例として、タンパク質老廃物の分解成分である硫化水素、メチルメルカプタン及びジメチルメルカプタンなどの揮発性硫化物を除去するための研究が進められている。これは、その効果が限定的に認められる口臭発生に関わる微生物の制御に比べてその効果が優れるだろうと評価されており、これに関連して、効果的な口臭除去を通じて口臭を改善できる方法に関する研究の必要性が増大している。 In addition, in order to suppress bad breath that occurs in the oral cavity, substances that cause mouth teeth, such as volatile sulfides such as hydrogen sulfide, methyl mercaptan, and dimethyl mercaptan, which are decomposition components of protein wastes, are removed. Research is underway to This has been evaluated as being more effective than the control of microbes involved in halitosis, which has limited efficacy. Research needs are increasing.
本発明は、既存の歯磨き粉などとは異なり、効果的な口臭除去を通じて、口臭を改善できる口腔用組成物を提供することを目的とする。 An object of the present invention is to provide an oral composition capable of improving bad breath through effective removal of bad breath, unlike conventional toothpastes.
本発明は、前述したように、口臭の原因となる硫化水素、メチルメルカプタン及びジメチルメルカプタンなどの揮発性硫化物を除去するために、前記揮発性硫化物を発生させるタンパク質老廃物の分解成分を効果的に除去できる口腔組成物である口臭改善用口腔組成物を提供する。 As described above, in order to remove volatile sulfides such as hydrogen sulfide, methyl mercaptan and dimethyl mercaptan that cause bad breath, the present invention is effective in decomposing protein waste products that generate volatile sulfides. To provide an oral composition for improving halitosis, which is an oral composition that can be effectively removed.
具体的には、本発明の口臭改善用口腔組成物は、キトサン及び緑茶抽出物を有効成分として含む口臭改善用口腔組成物であってもよい。 Specifically, the oral cavity composition for improving halitosis of the present invention may be an oral composition for improving halitosis containing chitosan and a green tea extract as active ingredients.
前記キトサンは、重量平均分子量(Mw)が10,000Da~57,000Daであってもよい。 The chitosan may have a weight average molecular weight (Mw) of 10,000 Da to 57,000 Da.
こうした点で、前記口臭改善用口腔組成物は、キトサン及び緑茶抽出物を有効成分として含む口臭改善用口腔組成物であり、前記キトサンは、重量平均分子量(Mw)が10,000Da~57,000Daであることを特徴とするものであってもよい。 In this respect, the oral composition for improving bad breath is an oral composition for improving bad breath containing chitosan and a green tea extract as active ingredients, and the chitosan has a weight average molecular weight (Mw) of 10,000 Da to 57,000 Da. It may be characterized by being
前記キトサンの含有量は、好ましくは、前記口臭改善用口腔組成物の重量を基準にして、0.01~0.05%(w/w)であってもよい。こうした側面から、前記口臭改善用口腔組成物は、前記口臭改善用口腔組成物100重量部を基準にして、前記キトサンの含有量が0.01~0.05重量部であるものであってもよい。 The chitosan content may preferably be 0.01 to 0.05% (w/w) based on the weight of the oral cavity composition for improving halitosis. From this aspect, the oral cavity composition for improving halitosis has a chitosan content of 0.01 to 0.05 parts by weight based on 100 parts by weight of the oral composition for improving halitosis. good.
前記緑茶抽出物は、前記緑茶抽出物中に含まれるカテキンの含有量によって口腔組成物全体に渋味を与えて口腔組成物全体の嗜好度を低下させる可能性があるので、前記緑茶抽出物の含有量は、前記緑茶抽出物に含まれるカテキンの含有量によって影響を受ける。 Due to the content of catechins contained in the green tea extract, the green tea extract may impart an astringent taste to the oral composition as a whole and reduce the palatability of the oral composition as a whole. The content is affected by the content of catechins contained in the green tea extract.
こうした側面から、前記緑茶抽出物の含有量は、前記緑茶抽出物に含まれているカテキンの含有量に基づいて調節され得るので、前記口臭改善用口腔組成物の重量を基準にして、前記緑茶抽出物の含有量は前記緑茶抽出物に含まれるカテキンの含有量が前記口臭改善用口腔組成物の重量を基準にして、0.1~0.2%(w/w)となるように調節することができる。 From this aspect, the content of the green tea extract can be adjusted based on the content of catechins contained in the green tea extract. The content of the extract is adjusted so that the content of catechins contained in the green tea extract is 0.1 to 0.2% (w/w) based on the weight of the oral composition for improving bad breath. can do.
従って、前記緑茶抽出物の含有量は、好ましくは、前記緑茶抽出物に含まれているカテキンの含有量を基準にして、前記口臭改善用口腔組成物100重量部を基準にして、前記カテキンの含有量が0.1~0.2重量部であってもよい。 Therefore, the content of the green tea extract is preferably based on the content of catechins contained in the green tea extract, and based on 100 parts by weight of the oral cavity composition for improving bad breath, the content of the catechins is The content may be 0.1 to 0.2 parts by weight.
また、前記口臭改善用口腔組成物は、ポリオール、ポリマー、殺菌剤、可溶化剤、抗菌成分、口臭除去有効成分、歯茎疾患予防成分、pH調節剤、保存剤、防腐剤、着香剤、甘味剤、香料、色素及び溶剤からなる群から選択された1種以上の追加成分をさらに含むものであってもよい。 In addition, the oral cavity composition for improving halitosis contains polyol, polymer, bactericide, solubilizer, antibacterial component, halitosis removing active component, gum disease preventive component, pH adjuster, preservative, antiseptic, flavoring agent, and sweetener. It may further comprise one or more additional ingredients selected from the group consisting of agents, fragrances, dyes and solvents.
本発明の口臭改善用口腔組成物は、天然物であるキトサンと緑茶抽出物を主成分として使用するものであるため、人体に有害な合成化合物の使用を最小限に抑えることができるので安全であるだけでなく、口臭除去効果に優れながらも渋味など使用する上で不便さを感じさせることなく嗜好度に優れて、消費者の使用感及び満足感を向上させる効果を有する。 The oral cavity composition for improving halitosis of the present invention uses chitosan and green tea extract, which are natural products, as the main ingredients, so it is safe because the use of synthetic compounds harmful to the human body can be minimized. In addition, it has an excellent effect of removing bad breath, but also has an excellent degree of palatability without causing discomfort such as astringency in use, and has the effect of improving the feeling of use and satisfaction of consumers.
本発明は、キトサン及び緑茶抽出物を有効成分として含む口臭改善用口腔組成物であり、
前記キトサンは、重量平均分子量(Mw)が10,000Da~57,000Daであり、
前記緑茶抽出物はカテキンを含むものであり、
前記キトサンの含有量は、前記口臭改善用口腔組成物100重量部を基準にして、0.01~0.05重量部であり、
前記緑茶抽出物の含有量は、前記緑茶抽出物に含まれているカテキンの含有量を基準にして、前記口臭改善用口腔組成物100重量部を基準にして、前記カテキンの含有量が0.1~0.2
であることを特徴とする口臭改善用口腔組成物に関する。
The present invention is an oral composition for improving bad breath containing chitosan and green tea extract as active ingredients,
The chitosan has a weight average molecular weight (Mw) of 10,000 Da to 57,000 Da,
The green tea extract contains catechins,
The content of the chitosan is 0.01 to 0.05 parts by weight based on 100 parts by weight of the oral composition for improving bad breath,
The content of the green tea extract is based on the content of catechins contained in the green tea extract, and based on 100 parts by weight of the oral cavity composition for improving bad breath, the content of the catechins is 0.5 parts by weight. 1 to 0.2
It relates to an oral cavity composition for improving bad breath characterized by
以下、本発明を詳しく説明するために本発明の好ましい実施例を記載する。下記の実施例は本発明を例示するためのものであって、本発明の権利範囲が下記の実施例によっていかなる形であれ限定されるものではなく、当業界で通常行われる変形なども本発明の範囲内に含まれる。 Preferred embodiments of the present invention are described below in order to explain the present invention in detail. The following examples are for the purpose of illustrating the present invention, and the scope of the present invention is not limited in any way by the following examples. included within the scope of
本発明は、キトサン及び緑茶抽出物を有効成分として含む口臭改善用口腔組成物に関する。 TECHNICAL FIELD The present invention relates to an oral composition for improving halitosis containing chitosan and green tea extract as active ingredients.
前記口臭改善用口腔組成物は、キトサン及び緑茶抽出物を有効成分として含む口臭改善用口腔組成物であり、前記キトサンは、重量平均分子量(Mw)が10,000Da~57,000Daであるものであってもよい。 The oral composition for improving bad breath is an oral composition for improving bad breath containing chitosan and a green tea extract as active ingredients, and the chitosan has a weight average molecular weight (Mw) of 10,000 Da to 57,000 Da. There may be.
前記口臭改善用口腔組成物は、前記口臭改善用口腔組成物100重量部を基準にして、前記キトサンの含有量が0.01~0.05重量部であるものであってもよい。 The oral cavity composition for improving halitosis may contain 0.01 to 0.05 parts by weight of chitosan based on 100 parts by weight of the oral composition for improving halitosis.
前記キトサンの含有量は、好ましくは、前記口臭改善用口腔組成物の重量を基準にして、0.01~0.05%(w/w)であってもよい。 The chitosan content may preferably be 0.01 to 0.05% (w/w) based on the weight of the oral cavity composition for improving halitosis.
前記緑茶抽出物はカテキンを含むものであってもよく、前記緑茶抽出物の含有量は、前記緑茶抽出物に含まれているカテキンの含有量を基準にして、前記口臭改善用口腔組成物100重量部を基準にして、前記カテキンの含有量が0.1~0.2重量部であってもよい。 The green tea extract may contain catechins, and the content of the green tea extract is based on the content of catechins contained in the green tea extract. The catechin content may be 0.1 to 0.2 parts by weight based on parts by weight.
前記緑茶抽出物はカテキンを含むものであってもよく、前記緑茶抽出物中に含まれるカテキンの含有量は、好ましくは、前記口臭改善用口腔組成物の重量を基準にして、0.1~0.2%(w/w)であってもよい。 The green tea extract may contain catechins, and the content of catechins contained in the green tea extract is preferably from 0.1 to 0.1, based on the weight of the oral composition for improving bad breath. It may be 0.2% (w/w).
前記口臭改善用口腔組成物は、ポリオール、ポリマー、殺菌剤、う蝕抑制剤、口臭除去有効成分、pH調節剤、保存剤、防腐剤、着香剤、甘味剤、香料、色素及び溶剤からなる群から選択された1種以上の追加成分をさらに含むものであってもよい。 The oral cavity composition for improving bad breath comprises a polyol, a polymer, a bactericide, a caries inhibitor, an active ingredient for removing bad breath, a pH adjuster, a preservative, an antiseptic, a flavoring agent, a sweetening agent, a fragrance, a pigment, and a solvent. It may further comprise one or more additional ingredients selected from the group.
本明細書において特に断りのない限り、平均分子量(average molecular weight)とは、分子量が異なる複数の分子種の混合物である高分子化合物の分子量、すなわち分子量が異なる複数の分子種の分子量の平均値を意味する。前記平均分子量は、数平均分子量、重量平均分子量のように、平均をとる方法を明示的に表示する。 Unless otherwise specified herein, the average molecular weight is the molecular weight of a polymer compound that is a mixture of multiple molecular species with different molecular weights, i.e. the average value of the molecular weights of multiple molecular species with different molecular weights. means The average molecular weight explicitly indicates the method of averaging, such as number average molecular weight and weight average molecular weight.
本明細書において特に断りのない限り、組成物とは、明示された成分を明示された量で含む生成物だけでなく、明示された量の明示された成分の配合物から直接又は間接的に生じる生成物を含むことを意味する。 Unless otherwise specified herein, a composition includes products containing the specified ingredients in the specified amounts, as well as products containing the specified ingredients in the specified amounts, either directly or indirectly from a blend of the specified ingredients in the specified amounts. It is meant to include the resulting products.
本明細書において特に断りのない限り、有効量とは、目的とする治療、軽減、抑制又は予防効果をもたらすのに効果的な本発明の抽出物又は組成物の量を意味する。 Unless otherwise specified herein, effective amount means an amount of the extract or composition of the present invention effective to bring about the desired therapeutic, alleviating, suppressing or prophylactic effect.
本明細書において特に断りのない限り、可溶化剤(solubilizing agent)とは、水に溶解しない物質を可溶化するために使用される界面活性剤を意味する。前記界面活性剤は、陰イオン界面活性剤、両性界面活性剤又は非イオン界面活性剤であってもよく、一例として、アミド系非イオン界面活性剤、ラウリル硫酸ナトリウム、ポリオキシエチレン-ポリオキシプロピレンの共重合体(ポロキサマー)、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、タウレート系などの陰イオン界面活性剤又はベタイン系両性界面活性剤であってもよい。 Unless otherwise specified herein, solubilizing agent means a surfactant used to solubilize substances that are insoluble in water. The surfactant may be an anionic surfactant, an amphoteric surfactant or a nonionic surfactant, examples of which include amide-based nonionic surfactants, sodium lauryl sulfate, polyoxyethylene-polyoxypropylene (poloxamer), polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, anionic surfactants such as taurate-based or betaine-based amphoteric surfactants.
本発明の発明者らは、既存の口臭改善用口腔組成物が主に口臭を除去するために、口臭の原因物質である硫化水素、メチルメルカプタン及びジメチルメルカプタンなどの揮発性硫化物を除去するためにタンパク質老廃物の分解成分を発生させる微生物の制御に集中し、そのために既存の口臭改善用口腔組成物に天然物由来の抗菌物質や化合物由来の抗菌物質を添加したにもかかわらず、口臭除去効果が限定的であることに着目し、微生物の制御ではなくタンパク質老廃物自体に焦点を当ててタンパク質老廃物を効果的に除去できる口腔組成物に関する研究を進めた。 The inventors of the present invention have found that existing oral compositions for improving bad breath mainly remove volatile sulfides such as hydrogen sulfide, methyl mercaptan and dimethyl mercaptan, which are causative substances of bad breath, in order to remove bad breath. In spite of the fact that the control of microorganisms that generate decomposition components of protein wastes is concentrated on the control of microorganisms that generate components that decompose protein wastes, and for that purpose, antibacterial substances derived from natural products and antibacterial substances derived from compounds are added to existing oral compositions for improving halitosis, bad breath can be removed. Focusing on the limited efficacy, research was conducted on oral compositions capable of effectively removing protein wastes, focusing on the protein wastes themselves rather than the control of microorganisms.
安全性が問題となる人工化合物ではなく、安全性が検証された天然物をもとにこれらの研究を進めた結果、キトサンと緑茶抽出物を併用する場合、簡単なうがいだけでもタンパク質老廃物の除去が容易であることを確認し、このようなタンパク質老廃物の除去効果がキトサンの分子量によって影響を受け、緑茶抽出物の添加量も老廃物の除去効果に影響を及ぼすことを確認しただけでなく、キトサン添加量と緑茶抽出物、具体的に緑茶抽出物中に含まれるカテキンの含有量が口腔組成物全体の嗜好度に影響を及ぼすことを確認して、前記実験結果に基づいて、キトサンの重量平均分子量(Mw)が11,170Daであり、キトサンの含有量が0.05%(w/w)であり、緑茶抽出物の含有量が前記緑茶抽出物に含まれているカテキンの含有量を基準にして、0.1~0.2%(w/w)である場合が最も適していることを確認した。前記結果に基づいて作製された口臭改善用口腔組成物は、天然物であるキトサンと緑茶抽出物を主成分として使用するものであるため、人体に有害な合成化合物の使用を最小限に抑えることができるので安全であるだけでなく、口臭除去効果に優れながらも渋味など使用する上で不便さを感じさせることなく嗜好度に優れて、消費者の使用感及び満足感を向上させて、既存の口臭改善用口腔組成物が有する問題を解決できるということに基づいて本発明を完成した。 As a result of conducting these studies based on natural products whose safety has been verified, rather than artificial compounds with safety issues, it was found that when chitosan and green tea extract are used in combination, even a simple gargling can eliminate protein waste. It was only confirmed that the removal was easy, the effect of removing protein wastes was affected by the molecular weight of chitosan, and the amount of green tea extract added also affected the effect of removing wastes. However, it was confirmed that the amount of chitosan added and the green tea extract, specifically the content of catechins contained in the green tea extract, affect the palatability of the oral composition as a whole. has a weight average molecular weight (Mw) of 11,170 Da, a chitosan content of 0.05% (w/w), and a green tea extract content of catechins contained in the green tea extract We have found that 0.1 to 0.2% (w/w), based on the amount, is most suitable. The oral cavity composition for improving bad breath produced based on the above results uses chitosan and green tea extract, which are natural products, as main ingredients, so that the use of synthetic compounds harmful to the human body is minimized. Not only is it safe because it can remove bad breath, but it is also highly palatable without causing inconvenience such as astringency when used, improving the feeling of use and satisfaction of consumers. The present invention was completed based on the fact that the problems of the existing oral compositions for improving bad breath can be solved.
以下、本発明をより詳しく説明する。 The present invention will be described in more detail below.
本発明は、既存の合成界面活性剤を使用するペーストタイプの歯磨き粉が有する問題点を解決するために、合成界面活性剤を使用しなくとも、一定水準の粘性が持続して、滑らかな使用感など優れた使用感を確保できるペーストタイプの口臭改善用口腔組成物に関する。 In order to solve the problems of existing paste-type toothpastes that use synthetic surfactants, the present invention maintains a certain level of viscosity without using synthetic surfactants and provides a smooth feeling of use. The present invention relates to a paste-type oral composition for improving halitosis that can ensure an excellent feeling of use.
本発明の口臭改善用口腔組成物は、キトサン及び緑茶抽出物を有効成分として含む口臭改善用口腔組成物に関する。 The oral cavity composition for improving halitosis of the present invention relates to an oral composition for improving halitosis containing chitosan and a green tea extract as active ingredients.
前記キトサンは、タンパク質老廃物の除去効果及び口臭の原因となる硫化水素、メチルメルカプタン及びジメチルメルカプタンなどの揮発性硫化物の生成抑制効果の側面から、重量平均分子量(Mw)が10,000Da~57,000Da、好ましくは10,000Da~13,000Da、より好ましくは11,150~11,200Da、さらに好ましくは11,170Daであってもよい。 The chitosan has a weight-average molecular weight (Mw) of 10,000 Da to 57 in terms of the effect of removing protein wastes and the effect of suppressing the production of volatile sulfides such as hydrogen sulfide, methyl mercaptan and dimethyl mercaptan that cause bad breath. ,000 Da, preferably 10,000 Da to 13,000 Da, more preferably 11,150 to 11,200 Da, even more preferably 11,170 Da.
こうした点で、前記口臭改善用口腔組成物は、キトサン及び緑茶抽出物を有効成分として含む口臭改善用口腔組成物であり、前記キトサンは、重量平均分子量(Mw)が10,000Da~57,000Daであることを特徴とするものであってもよい。 In this respect, the oral composition for improving bad breath is an oral composition for improving bad breath containing chitosan and a green tea extract as active ingredients, and the chitosan has a weight average molecular weight (Mw) of 10,000 Da to 57,000 Da. It may be characterized by being
前記キトサン(chitosan)は、カニ、エビなどの甲殻類の殻に存在するキチン(chitin)を高温、強アルカリで処理して脱アセチル化させた天然高分子物質を意味する。前記キトサンは、抗菌活性、抗真菌活性、免疫活性の増強効果などの様々な生理機能性を有する物質である。 The chitosan is a natural polymer obtained by deacetylating chitin present in the shells of crustaceans such as crabs and shrimps with high temperature and strong alkali. The chitosan is a substance having various physiological functions such as antibacterial activity, antifungal activity, and immune activity enhancing effect.
前記キトサンは口腔細菌の生育を抑制して歯茎疾患を予防すると同時に、キトサンの吸着、凝集作用によって口腔の清潔を維持することができる。前記キトサンは分子内に、水素結合が非常に強いアセチルアミノ基を有しているため、水に溶解しない特性があるが、前記キトサンを低分子、一例として、分子量10,000~70,000Daに低分子化する場合水溶性を有する。前記キトサンは、好ましくは、水に溶解可能な水溶性キトサンでありながら、効果に優れた高分子量のキトサン、一例として、キチンを脱アセチル化させて得られた通常のキトサン(非水溶性キトサン)にカルボキシエチル(Carboxyethyl)基を結合させたカルボキシエチルキトサン(N-Carboxyethyl Chitosan)であってもよい。 The chitosan inhibits the growth of oral bacteria to prevent gum disease, and at the same time, it can keep the oral cavity clean due to its adsorption and cohesive action. Since the chitosan has an acetylamino group with a very strong hydrogen bond in its molecule, it has a characteristic of not being dissolved in water. It has water solubility when it is made into a low molecular weight compound. The chitosan is preferably a high-molecular-weight chitosan that is highly effective while being water-soluble chitosan, such as ordinary chitosan obtained by deacetylating chitin (water-insoluble chitosan). It may be carboxyethyl chitosan (N-Carboxyethyl Chitosan) in which a carboxyethyl group is bound to .
前記キトサンの含有量は、口腔組成物の全体的な嗜好度と使用感の側面から、好ましくは、前記口臭改善用口腔組成物の重量を基準にして、0.01~0.05%(w/w)であってもよい。 The chitosan content is preferably 0.01 to 0.05% (w /w).
こうした側面から、前記口臭改善用口腔組成物は、前記口臭改善用口腔組成物100重量部を基準にして、前記キトサンの含有量が0.01~0.05重量部であるものであってもよい。 From this aspect, the oral cavity composition for improving halitosis has a chitosan content of 0.01 to 0.05 parts by weight based on 100 parts by weight of the oral composition for improving halitosis. good.
前記緑茶抽出物は、前記緑茶抽出物中に含まれるカテキンの含有量によって口腔組成物全体に渋味を与えて口腔組成物全体の嗜好度を低下させる可能性があるので、前記緑茶抽出物の含有量は、前記緑茶抽出物に含まれるカテキンの含有量によって影響を受ける。 Due to the content of catechins contained in the green tea extract, the green tea extract may impart an astringent taste to the oral composition as a whole and reduce the palatability of the oral composition as a whole. The content is affected by the content of catechins contained in the green tea extract.
こうした側面から、前記緑茶抽出物の含有量は、前記緑茶抽出物に含まれているカテキンの含有量に基づいて調節され得るので、前記口臭改善用口腔組成物の重量を基準にして、前記緑茶抽出物の含有量は前記緑茶抽出物に含まれるカテキンの含有量が前記口臭改善用口腔組成物の重量を基準にして、0.1~0.2%(w/w)となるように調節することができる。 From this aspect, the content of the green tea extract can be adjusted based on the content of catechins contained in the green tea extract. The content of the extract is adjusted so that the content of catechins contained in the green tea extract is 0.1 to 0.2% (w/w) based on the weight of the oral composition for improving bad breath. can do.
従って、前記緑茶抽出物の含有量は、好ましくは、前記緑茶抽出物に含まれているカテキンの含有量を基準にして、前記口臭改善用口腔組成物100重量部を基準にして、前記カテキンの含有量が0.1~0.2重量部であってもよい。 Therefore, the content of the green tea extract is preferably based on the content of catechins contained in the green tea extract, and based on 100 parts by weight of the oral cavity composition for improving bad breath, the content of the catechins is The content may be 0.1 to 0.2 parts by weight.
本発明において、緑茶抽出物はチャノキの葉の抽出物を意味する。 In the present invention, green tea extract means tea leaf extract.
前記チャノキ(tea plant)はチャノキ科に属する常緑喬木又は常緑広葉低木であり、学名はCamellia sinensisである。チベットと中国四川省との境界に当たる山岳地帯が原産地として知られており、熱帯地方、亜熱帯地方及び温帯地方に自生し、現在は主に韓国、日本、中国、インド及び東南アジア地域に分布している。前記チャノキには変種が多く、これらの変種はその形がそれぞれ大きく異なる。主に、中国や日本で栽培される小葉種は、自然状態でも高さが約2m~約3m程度まで成長する低木であり、インドのアッサム地方の大葉種は、高さが約15m~約30mに達する喬木である。 The tea plant is an evergreen tea tree or evergreen broad-leaved shrub belonging to the Tea plant family, and its scientific name is Camellia sinensis. Known as the place of origin, the mountainous region on the border of Tibet and Sichuan Province in China grows naturally in tropical, subtropical and temperate regions, and is now mainly distributed in Korea, Japan, China, India and Southeast Asia. . There are many varieties of the tea tree, and these varieties differ greatly in shape. The small-leaved species mainly cultivated in China and Japan are shrubs that grow to a height of about 2 to 3 m even under natural conditions. It is Takagi who reaches .
前記チャノキの葉は品種や位置によって変異が大きいが、主に長さ6cm~20cm及び幅3cm~4cmの長い楕円形であり、縁に鈍い鋸歯があり、先端と下部が尖っているのが特徴である。葉の質は硬くてやや厚く、表面に光沢がある。品種によって葉色の濃薄に差があり、しわにも変化がある。幼葉や幼芽の裏面には柔らかい毛がある。韓国では、智異(チリ)山に育つ野生種は中国産小葉種であり、栽培茶の場合は中国産小葉種を改良した日本産やぶきた種が主に栽培される。 The leaves of the tea tree vary greatly depending on the variety and position, but are mainly long oval with a length of 6 cm to 20 cm and a width of 3 cm to 4 cm. is. The leaves are hard and somewhat thick with a glossy surface. There are differences in leaf color intensity and wrinkles depending on the variety. The undersides of young leaves and seedlings are covered with soft hairs. In South Korea, the wild variety grown in Mt. Jiri (Chile) is the Chinese small-leaved variety, and the cultivated tea is mainly the Japanese Yabukita variety, which is an improved version of the Chinese small-leaved variety.
前記緑茶抽出物、すなわちチャノキの葉の抽出物は、通常の植物抽出物の製造方法に従って製造されたものであってもよい。より具体的には、不純物を除去したチャノキの葉、前記チャノキの葉の粉砕物又は前記チャノキの葉の粉砕物の乾燥物に対して溶媒抽出法、超臨界抽出法又は超音波抽出法を行って抽出したものであってもよい。こうした意味で、前記抽出物は、抽出溶媒で抽出した溶媒抽出物、超臨界抽出物、すなわち超臨界流体による超臨界抽出を通じた抽出物又は超音波抽出物であってもよい。 The green tea extract, ie, tea leaf extract, may be prepared according to a general method for preparing plant extracts. More specifically, a solvent extraction method, a supercritical extraction method, or an ultrasonic extraction method is performed on tea tree leaves from which impurities have been removed, the tea tree leaf pulverized material, or the dry material of the tea tree leaf pulverized material. It may be extracted by In this sense, the extract may be a solvent extract extracted with an extraction solvent, a supercritical extract, ie an extract through supercritical extraction with a supercritical fluid, or an ultrasonic extract.
前記溶媒抽出物は、当業界で公知の通常の方法に従って、通常の温度と圧力の条件下で通常の溶媒、具体的には抽出溶媒を使用して製造されたものであってもよい。 The solvent extract may be prepared using a common solvent, specifically an extraction solvent, under common temperature and pressure conditions according to common methods known in the art.
前記抽出溶媒は、天然物抽出に使用できる水、有機溶媒又はこれらの混合溶媒、好ましくは水、炭素数1~5のアルコール及びこれらの混合物からなる群から選択されたいずれか一つ、より好ましくは水であってもよい。前記有機溶媒は、メタノール、エタノールなどの炭素数1~5の直鎖又は分枝鎖アルコール、エチルアセテート又はアセトンなどの極性溶媒とヘキサン又はジクロロメタンの非極性溶媒、炭素数3~5のケトンなどの中性溶媒又はこれらの混合溶媒であってもよく、好ましくは30~90%のエタノールなどの炭素数1~5の直鎖又は分枝鎖アルコール水溶液、又は30~90%の炭素数3~5のケトン、より好ましくは50~80%のエタノール水溶液又は50~80%のアセトン水溶液、さらに好ましくは60~75%のエタノール水溶液であってもよい。 The extraction solvent is any one selected from the group consisting of water, an organic solvent, or a mixed solvent thereof, preferably water, an alcohol having 1 to 5 carbon atoms, and a mixture thereof, which can be used for extracting natural products, more preferably. can be water. The organic solvent includes linear or branched alcohols having 1 to 5 carbon atoms such as methanol and ethanol, polar solvents such as ethyl acetate or acetone, nonpolar solvents such as hexane or dichloromethane, and ketones having 3 to 5 carbon atoms. A neutral solvent or a mixed solvent thereof may be used, preferably a straight or branched chain alcohol solution having 1 to 5 carbon atoms such as 30 to 90% ethanol, or 30 to 90% carbon atoms 3 to 5 ketone, more preferably 50-80% ethanol aqueous solution or 50-80% acetone aqueous solution, more preferably 60-75% ethanol aqueous solution.
前記抽出溶媒は、実質的に同じ効果を示すことができる当業者に公知の通常の他の溶媒に代替することができる。 The extraction solvent can be replaced by other common solvents known to those skilled in the art that can exhibit substantially the same effect.
前記超臨界抽出物は、二酸化炭素を流体とし減圧及び高温による超臨界条件で行う超臨界抽出法又は超臨界流体抽出法(supercritical fluid extraction)によって抽出されたものであり得る。一般に、超臨界流体は、気体が高温高圧の条件で臨界点に達したときに有する液体及び気体の性質を持っており、化学的に非極性溶媒と類似した極性を有しているため、脂溶性物質の抽出に有効である。具体的には、前記二酸化炭素は、超臨界流体機器の作動によって圧力及び温度が臨界点まで達する過程を経て、液体及び気体の性質を同時に有する超臨界流体となり、その結果、脂溶性溶質に対する溶解度が増加する。従って、前記超臨界二酸化炭素が一定量の試料を含む抽出容器を通過すると、試料に含まれた脂溶性物質は超臨界二酸化炭素に抽出され、脂溶性物質を抽出した後、抽出容器に残っている試料に再び少量の共溶媒が含まれた超臨界二酸化炭素を流して通過させると、純粋な超臨界二酸化炭素だけでは抽出されなかった成分が抽出されて出てくるようにすることができる。 The supercritical extract may be obtained by supercritical extraction or supercritical fluid extraction using carbon dioxide as a fluid under supercritical conditions of reduced pressure and high temperature. In general, supercritical fluids have the properties of liquids and gases when gases reach a critical point under high temperature and pressure conditions. Effective for extracting soluble substances. Specifically, the carbon dioxide becomes a supercritical fluid having properties of liquid and gas at the same time through a process in which the pressure and temperature reach a critical point due to the operation of the supercritical fluid device, and as a result, solubility in fat-soluble solutes increases. Therefore, when the supercritical carbon dioxide passes through the extraction container containing a certain amount of the sample, the fat-soluble substances contained in the sample are extracted by the supercritical carbon dioxide, and after the fat-soluble substances are extracted, they remain in the extraction container. By passing supercritical carbon dioxide containing a small amount of co-solvent again through the sample, it is possible to extract the components that were not extracted with pure supercritical carbon dioxide.
こうした側面から、前記超臨界抽出法に使用される超臨界流体は、超臨界二酸化炭素又は二酸化炭素にさらに共溶媒を混合した混合流体であってもよい。前記共溶媒は、クロロホルム、エタノール、メタノール、水、エチルアセテート、ヘキサン、ジエチルエーテル及びこれらの混合物からなる群から選択されるいずれか一つであってもよい。 From this aspect, the supercritical fluid used in the supercritical extraction method may be supercritical carbon dioxide or a mixed fluid obtained by mixing carbon dioxide with a co-solvent. The co-solvent may be any one selected from the group consisting of chloroform, ethanol, methanol, water, ethyl acetate, hexane, diethyl ether and mixtures thereof.
前記抽出過程で使用された二酸化炭素は室温で空気中に揮発するため、前記方法で得られた抽出物を化粧料組成物として用いることができ、共溶媒の場合、減圧蒸発器で除去することができる。 Since the carbon dioxide used in the extraction process volatilizes into the air at room temperature, the extract obtained by the above method can be used as a cosmetic composition. can be done.
前記超音波抽出物は、超音波抽出法によって抽出されたことを意味する。前記超音波抽出法は、超音波振動によって発生するエネルギーを利用する抽出方法であり、前記超音波が抽出溶媒中の試料に伝達されると、前記超音波によって温度が上昇するようになり、高い局部温度によって周囲に位置する反応物粒子の運動エネルギーを大きくするため、反応に必要な十分なエネルギーを得るようになり、超音波エネルギーの衝撃効果で高い圧力が誘導されて、試料に含まれた物質と抽出溶媒の混合効果を高めてくれて抽出効率が上昇することになる。 The ultrasonic extract means extracted by an ultrasonic extraction method. The ultrasonic extraction method is an extraction method that utilizes energy generated by ultrasonic vibrations. When the ultrasonic waves are transmitted to the sample in the extraction solvent, the temperature rises due to the ultrasonic waves. The local temperature increases the kinetic energy of the surrounding reactant particles, so that sufficient energy is available for the reaction, and the impact effect of the ultrasonic energy induces a high pressure to be contained in the sample. It enhances the mixing effect of the substance and the extraction solvent, thus increasing the extraction efficiency.
前記超音波抽出法に使用できる抽出溶媒は、クロロホルム、エタノール、メタノール、水、エチルアセテート、ヘキサン、ジエチルエーテル及びこれらの混合物からなる群から選択されるいずれか一つであってもよい。 The extraction solvent that can be used in the ultrasonic extraction method may be any one selected from the group consisting of chloroform, ethanol, methanol, water, ethyl acetate, hexane, diethyl ether, and mixtures thereof.
前記溶媒抽出法は、冷浸抽出法、温浸抽出法、加圧抽出法又は還流抽出法であり得る。 The solvent extraction method may be cold extraction, digestion extraction, pressure extraction or reflux extraction.
また、前記抽出物は抽出過程を遂行した後、減圧濾過過程を行うか、或いは追加で濃縮及び/又は凍結乾燥を行って濃縮するか、或いは溶媒を除去することができる。従って、本発明におけるチャノキの葉の抽出物は、通常の方法で乾燥された抽出物の乾燥物と通常の方法で濃縮された抽出物の濃縮物、前記抽出物、乾燥物又は濃縮物の希釈液を含む意味で使用される。前記得られたチャノキの葉の抽出物は、使用するときまで急速冷凍冷蔵庫(deep freezer)に保管することができる。 In addition, after performing the extraction process, the extract may be subjected to vacuum filtration, or may be additionally concentrated and/or freeze-dried to concentrate, or the solvent may be removed. Therefore, the tea tree leaf extract in the present invention consists of a dried extract dried by a conventional method, a concentrate of an extract concentrated by a conventional method, and a diluted extract, dried extract or concentrate. Used in the sense of including liquid. The obtained tea leaf extract can be stored in a deep freezer until use.
また、前記口臭改善用口腔組成物は、ポリオール、ポリマー、可溶化剤、抗菌成分、口臭除去有効成分、歯茎疾患予防成分、pH調節剤、保存剤、防腐剤、着香剤、甘味剤、香料、色素及び溶剤からなる群から選択された1種以上の追加成分をさらに含むものであってもよい。 In addition, the oral cavity composition for improving halitosis includes polyol, polymer, solubilizer, antibacterial component, halitosis removing active component, gum disease preventive component, pH adjuster, preservative, antiseptic, flavoring agent, sweetener, flavoring agent. , a pigment, and a solvent.
本発明の口臭改善用口腔組成物は、前記有効成分の他に当業界で通常用いられる口腔組成物に含まれる補助成分を、当業者が容易に選択して添加することができる。 A person skilled in the art can easily select and add to the oral cavity composition for improving bad breath of the present invention, in addition to the above active ingredients, auxiliary components contained in oral compositions commonly used in the art.
前記可溶化剤とは、水に溶解しない物質を可溶化するために使用される界面活性剤のことを意味し、一例として、陰イオン界面活性剤、両性界面活性剤又は非イオン界面活性剤であってもよく、一例として、アミド系非イオン界面活性剤、ラウリル硫酸ナトリウム、ポリオキシエチレン-ポリオキシプロピレンの共重合体(ポロキサマー)、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、タウレート系などの陰イオン界面活性剤又はベタイン系両性界面活性剤であってもよい。 The solubilizer means a surfactant used to solubilize a substance that is insoluble in water, and examples thereof include anionic surfactants, amphoteric surfactants and nonionic surfactants. Examples include amide nonionic surfactant, sodium lauryl sulfate, polyoxyethylene-polyoxypropylene copolymer (poloxamer), polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, taurate It may also be an anionic surfactant such as a betaine-based amphoteric surfactant.
前記抗菌成分とは、抗菌活性を有する物質であり、虫歯菌、歯周炎原因菌又は歯齦炎原因菌などに対する抗菌活性を有する成分を意味する。一例として、強い浸透圧効果を発揮できる塩化ナトリウムや前記虫歯菌、歯周炎原因菌、歯齦炎原因菌などに対する抗菌活性を有する天然抽出物、一例として、グレープフルーツ種子抽出物、プロポリス抽出液、蒲公英抽出物、桔梗濃縮エキス、黄柏濃縮エキス、ペパーミント抽出物、松葉抽出物、柳抽出物、海藻類抽出物又は天然抽出物由来の成分、一例として、トリクロサン(triclosan)、クルクマザントリザ油、塩化セチルピリジニウム(cetyl pyridium chloride)、塩化ベンゼトニウム(benzothonium chloride)、塩化ベンザルコニウム(benzalconium chloride)又はセチルピリジニウムクロリドやグルコン酸クロルヘキシジン(chlorohexidin gluconate)であってもよいが、これらに限定されるものではない。前記抗菌成分は、口臭改善用口腔組成物100重量部に0.01~10重量部又は0.05~5重量部の含有量で含まれてもよいが、これらに限定されるものではない。 The antibacterial component is a substance having antibacterial activity, and means a component having antibacterial activity against caries, periodontitis-causing bacteria, gingivitis-causing bacteria, and the like. Examples include sodium chloride, which can exert a strong osmotic effect, and natural extracts with antibacterial activity against the above-mentioned caries-causing bacteria, periodontitis-causing bacteria, and gingivitis-causing bacteria. extracts, bellflower concentrated extracts, yellow oak concentrated extracts, peppermint extracts, pine needle extracts, willow extracts, seaweed extracts or ingredients derived from natural extracts, examples include triclosan, curcumazan triza oil, cetyl chloride It may be, but not limited to, pyridinium chloride, benzothonium chloride, benzalconium chloride or cetylpyridinium chloride or chlorohexidine gluconate. . The antibacterial component may be contained in an amount of 0.01 to 10 parts by weight or 0.05 to 5 parts by weight based on 100 parts by weight of the oral composition for improving bad breath, but is not limited thereto.
前記口臭除去有効成分は、非発酵性糖アルコール(nonfermented sugar alcohol)、天然抽出物(extracts)、無機化合物(inorganic compounds)、酵素(enzyme)、酵素阻害剤(enzyme inhibitor)などであってもよい。 The halitosis-removing active ingredients may be non-fermented sugar alcohols, natural extracts, inorganic compounds, enzymes, enzyme inhibitors, and the like. .
前記非発酵性糖アルコールは、キシリトール(xylitol)、ソルビトール(sorbitol)、エリスリトール(erythritol)、マンニトール(mannitol)、マルチトール(maltitol)、ラクチトール(lactitol)、パラチニトール(palatinitol)、パラチノース(palatinose)、オリゴ糖(oligosaccharide)などであってもよく、前記天然抽出物は、柿葉抽出物(pancil extract)、サンギナリア抽出物(Sanguinaria extract)、牡丹皮抽出物などであってもよく、前記無機化合物(inorganic compounds)は、塩化亜鉛(zinc chloride)、グルコン酸銅(cupper gluconate)、ピロリン酸ナトリウム(tetrasodium pyrophosphate,TSPP)、酸性ピロリン酸ナトリウム(sodium acid pyrophosphate,SAPP)、ヘキサメタリン酸ナトリウム(sodium hexametaphosphate,SHMP)、トリポリリン酸ナトリウム(sodium tripolyphosphate,STP)、トリポリリン酸ナトリウムカリウム(sodium potassium tripolyphosphate,SKTP)、ピロリン酸カリウム(tetrapotassium pyrophosphate,TKPP)、酸性メタポリリン酸ナトリウム(acidic sodium meta-polyphosphate)、酸性ポリリン酸ナトリウム(acidic sodium polyphosphate)であってもよく、前記酵素(enzyme)は、デキストラナーゼ(dextranase)、ブドウ糖酸化酵素(glucose oxidase)、グルコースペルオキシダーゼ(glucose peroxidase)、ラクトペルオキシダーゼ(lactoperoxidase)、グルカナーゼ(glucanase)、プロテアーゼ(protease)又はリゾチーム(lysozyme)であってもよく、前記酵素阻害剤は、ペプチド(peptides)阻害剤及びコラゲナーゼ阻害剤など、口腔内の口臭発生に関与する酵素の阻害剤であってもよい。 The non-fermentable sugar alcohols include xylitol, sorbitol, erythritol, mannitol, maltitol, lactitol, palatinitol, palatinose, oligo sugar (oligosaccharide), etc., the natural extract may be persimmon leaf extract, Sanguinaria extract, peony bark extract, etc.; compounds include zinc chloride, copper gluconate, tetrasodium pyrophosphate (TSPP), sodium acid pyrophosphate (SAPP), sodium hexametaphosphate (SAPP) hexametaphosphate, SHMP) , sodium tripolyphosphate (STP), sodium potassium tripolyphosphate (SKTP), tetrapotassium pyrophosphate (TKPP), sodium metapolyphosphate (acidics odium meta-polyphosphate), sodium acid polyphosphate ( The enzyme may be dextranase, glucose oxidase, glucose peroxidase, lactoperoxidase, glucanase. canase), It may be a protease or lysozyme, and the enzyme inhibitor may be an inhibitor of enzymes involved in oral halitosis generation, such as peptides inhibitors and collagenase inhibitors. .
前記口臭除去有効成分は、単独又は2種以上を混合して使用することができる。 The above-mentioned active ingredients for removing bad breath can be used alone or in combination of two or more.
前記口臭除去有効成分は、前記口臭改善用口腔組成物の重量を基準にして、0.001~30重量%又は0.01~10重量%の濃度で添加することができる。 The active ingredient for removing bad breath can be added at a concentration of 0.001 to 30% by weight or 0.01 to 10% by weight based on the weight of the oral composition for improving bad breath.
前記歯茎疾患予防成分は、塩化ナトリウム、酢酸トコフェロール、塩酸ピリドキシン、アラントイン、アラントインクロルヒドロキシアルミニウム、トラネキサム酸又はアミノカプロン酸であってもよい。 The gum disease preventive ingredient may be sodium chloride, tocopherol acetate, pyridoxine hydrochloride, allantoin, allantoin chlorhydroxyaluminum, tranexamic acid or aminocaproic acid.
前記歯茎疾患予防成分は、単独又は2種以上を混合して使用することができる。 The gum disease-preventing component can be used alone or in combination of two or more.
前記歯茎疾患予防成分は、前記口臭改善用口腔組成物の重量を基準にして、0.001~30重量%又は0.01~10重量%の濃度で添加することができる。 The component for preventing gum disease may be added at a concentration of 0.001 to 30% by weight or 0.01 to 10% by weight based on the weight of the oral cavity composition for improving halitosis.
前記pH調節剤は、pHを調節したり、pHに敏感な有効成分、一例として、抗菌成分や薬効物質のためにpHの変化を緩衝するための物質を意味する。前記pH調節剤は、リン酸ナトリウム、リン酸二ナトリウム、リン酸三ナトリウム、クエン酸ナトリウム、炭酸水素ナトリウム、ピロリン酸ナトリウム、クエン酸(citric acid)、リンゴ酸(malic acid)、コハク酸(succinic acid)、酒石酸(tartar acid)、ギ酸(formic acid)又は乳酸(lactic acid)であってもよい。 The pH adjuster means a substance for adjusting pH or buffering changes in pH for pH-sensitive active ingredients, such as antibacterial ingredients and medicinal substances. The pH adjuster includes sodium phosphate, disodium phosphate, trisodium phosphate, sodium citrate, sodium bicarbonate, sodium pyrophosphate, citric acid, malic acid, succinic acid, acid), tartar acid, formic acid or lactic acid.
前記pH調節剤は、単独又は2種以上を混合して使用することができる。 The pH adjusters may be used alone or in combination of two or more.
前記pH調節剤は、前記口臭改善用口腔組成物の重量を基準にして、0.001~30重量%又は0.01~10重量%の濃度で添加することができる。 The pH adjuster may be added in a concentration of 0.001 to 30% by weight or 0.01 to 10% by weight based on the weight of the oral composition for improving bad breath.
前記着香剤は、口臭改善用口腔組成物に爽やかさを与え、不潔な臭いを抑制して使用感と嗜好度を向上させる目的で付加される成分であり、一例として、高麗人参抽出物、プロポリス抽出物、みかん油、L-メントール、クールミント香(HF-61399)、ミント香着香剤又は調合香料(リンゴ香、HF-30630)などであってもよい。 The flavoring agent is a component that is added for the purpose of imparting freshness to the oral cavity composition for improving bad breath, suppressing unclean odors, and improving usability and palatability. Examples include ginseng extract, Propolis extract, mandarin orange oil, L-menthol, cool mint scent (HF-61399), mint scent flavoring agent or mixed flavoring (apple scent, HF-30630) may be used.
前記甘味剤は、口臭改善用口腔組成物にある程度の甘味を与え、清涼感などを付与するための目的で付加される成分であり、一例として、サッカリンナトリウム、サッカリンナトリウム水和物、アスパルテーム、ステビオシド、ステビオール配糖体、キシリトール、D-キシロース(D-Xylose)、グリチルリチン酸、カモミール抽出物、セージエキス又はプロポリス抽出物であってもよい。 The sweetening agent is a component that is added for the purpose of imparting a certain degree of sweetness to the oral cavity composition for improving bad breath and imparting a refreshing feeling. Glycosides, xylitol, D-Xylose, glycyrrhizic acid, chamomile extract, sage extract or propolis extract.
前記香料は、食用可能な香料が使用され、一例として、メントール(Mentol)、アネトール(Anetol)、オイゲノール(Eugenol)、リモネン(Limonene)、オシメン(Ocimene)、n-ドデシルアルコール(n-Dodecyl Alcohol)、シトロネロール(Citronellol)、α-テルピネオール(a-Terpineol)、サリチル酸メチル(Methyl salicylate)、メチルアセテート(Methyl Acetate)、シトロネリルアセテート(Citronellyl Acetate)、シネオール(Cineol)、リナロール(Linalool)、エチルリナロール(Ethyl Linalool)、バニリン(Vanillin)、チモール(Thymol)、スペアミント(Spearmint)オイル、セージ(Sage)オイル、ローズマリー(Rosemary)オイル、シナモン(Cinamon)オイル、ペパーミントオイル、ユーカリプトールオイル又は果物抽出物であってもよい。 Edible flavors are used as the flavor, and examples thereof include Mentol, Anetol, Eugenol, Limonene, Ocimene, and n-Dodecyl Alcohol. , Citronellol, α-Terpineol, Methyl salicylate, Methyl Acetate, Citronellyl Acetate, Cineol, Linalool, Ethyllina Roll ( Ethyl Linalool), Vanillin, Thymol, Spearmint Oil, Sage Oil, Rosemary Oil, Cinnamon Oil, Peppermint Oil, Eucalyptol Oil or Fruit Extracts may be
前記色素は、主に食用色素が用いられる。 Food coloring is mainly used as the coloring matter.
前記溶剤は、一例として、水又は有機溶媒であってもよく、好ましくは水又はエタノール水溶液であってもよく、より好ましくは水であってもよい。 The solvent may be, for example, water or an organic solvent, preferably water or an aqueous ethanol solution, and more preferably water.
また、本発明の一具現例に係る口臭改善用口腔組成物は、口臭改善用口腔組成物に配合できる他の添加剤も含むことができる。 In addition, the oral composition for improving halitosis according to an embodiment of the present invention may also include other additives that can be added to the oral composition for improving halitosis.
前記口腔組成物は、口腔洗浄剤又はうがい剤であってもよく、うがいを容易にするために液状で製造されてもよいが、これらに限定されるものではない。 The oral composition may be, but is not limited to, a mouthwash or mouthwash, and may be manufactured in liquid form to facilitate gargling.
[製造例:口臭改善用口腔組成物の有効成分の製造] [Production Example: Production of Active Ingredient of Oral Composition for Improving Bad Breath]
口臭改善用口腔組成物を製造するために、有効成分であるキトサン及び緑茶抽出物を製造した。 Chitosan and green tea extract, which are active ingredients, were prepared in order to prepare an oral cavity composition for improving bad breath.
まず、キトサンは高分子キトサンを0.5%酢酸に添加して溶解した後、前記酢酸キトサン溶液にキトサン分解酵素を用いて適度な分子量となるように分解時間を調節して反応させた後、それぞれの時間別の分解酵素を処理したキトサン溶液をGPCを用いて平均分子量を測定して、重量平均分子量(MW)がそれぞれ108,210Da、55,130Da、11,170Da、5,208Da及び815Daとなるキトサンを得た。 First, chitosan is prepared by adding high-molecular-weight chitosan to 0.5% acetic acid and dissolving it, and then reacting the chitosan acetate solution with a chitosan-degrading enzyme to adjust the decomposition time so that the molecular weight is moderate. The average molecular weight of the chitosan solution treated with the degrading enzyme for each time was measured using GPC, and the weight average molecular weight (MW) was 108,210 Da, 55,130 Da, 11,170 Da, 5,208 Da and 815 Da, respectively. Chitosan was obtained.
また、前記緑茶抽出物の添加による嗜好度は、カテキンの渋味によって影響を受けるため、緑茶抽出物はカテキンの含有量が20%である緑茶抽出物の粉末を購入して使用した。 In addition, since the degree of palatability due to the addition of the green tea extract is affected by the astringency of the catechins, green tea extract powder containing 20% catechins was purchased and used.
前記購入した緑茶抽出物を口腔洗浄剤に添加して、緑茶抽出物の濃度が0.1%(w/w、カテキン含有量0.02%w/w)、0.3%(w/w、カテキン含有量0.06%w/w)、0.5%(w/w、カテキン含有量0.1%w/w)、1%(w/w、カテキン含有量0.2%w/w)となるように緑茶抽出物の添加量を調節して使用した。 The purchased green tea extract was added to the mouthwash, and the concentration of green tea extract was 0.1% (w/w, catechin content 0.02% w/w), 0.3% (w/w). , catechin content 0.06% w/w), 0.5% (w/w, catechin content 0.1% w/w), 1% (w/w, catechin content 0.2% w/w) w) was used by adjusting the amount of green tea extract added.
以下、本発明の属する技術分野における通常の知識を有する者が容易に実施できるよう本発明の実施例について詳細に説明する。しかし、本発明は種々の異なる形態で具現化することができ、ここで説明する実施例は本発明を例示するためのものであって、本発明が下記の実施例に限定されるものではない。 Hereinafter, embodiments of the present invention will be described in detail so that a person having ordinary knowledge in the technical field to which the present invention belongs can easily implement them. This invention may, however, be embodied in many different forms and the examples set forth herein are intended to be illustrative of the invention and should not be construed as limiting the invention. .
本実験は、それぞれ同じ実験を3回以上繰り返して行い、それぞれの実験結果から得られたデータは、SPSS/WIN 12.0version統計プログラム(Statistical Package for social Science,IBM,USA)を用いて、平均及び平均偏差(Mean±SEM)で表した。集団間の有意性を検証するために、一元配置分散分析(one-way ANOVA)を通じて分析し、事後検定(Post-Hoc test)は、ダンカンの多重範囲検定(Duncan’s multiple range test)によってP<0.05水準で各実験群間の有意性を検証した。 In this experiment, the same experiment was repeated three or more times, and the data obtained from each experimental result was averaged using SPSS/WIN 12.0 version statistical program (Statistical Package for social Science, IBM, USA) and mean deviation (Mean±SEM). To test for inter-group significance, analyzes were performed through one-way ANOVA, and Post-Hoc test was P by Duncan's multiple range test. Significance between each experimental group was verified at the <0.05 level.
[実験例:有効成分による口臭改善効果の確認] [Experimental example: Confirmation of bad breath improvement effect by active ingredients]
実験例1-1.嗜好度による有効成分の添加量の確認 Experimental example 1-1. Confirmation of the amount of active ingredient to be added according to taste
口腔組成物の場合、口臭除去効果が重要ではあるが、使用者の好みと嗜好によって様々な製品が選択され得るので、まず有効成分の添加量による嗜好度を添加して有効成分の含有量を確認した。 In the case of oral compositions, the effect of removing bad breath is important, but since various products can be selected according to the taste and preference of the user, the content of the active ingredient is adjusted by adding the degree of preference according to the amount of the active ingredient added. confirmed.
実験に使用した口腔組成物は、有効成分の他に溶剤として精製水を使用し、緑茶抽出物(表1)及びキトサン(表2)の他にメントール(0.05%(w/w))、キシリトール(3%(w/w))及びポリオキシエチレン硬化ヒマシ油(0.05%(w/w))をさらに添加して製造した。前記キトサンは、平均分子量が11,170Daであるキトサンを使用した。 The oral composition used in the experiment used purified water as a solvent in addition to the active ingredient, and menthol (0.05% (w / w)) in addition to green tea extract (Table 1) and chitosan (Table 2). , xylitol (3% (w/w)) and polyoxyethylene hydrogenated castor oil (0.05% (w/w)) were further added. Chitosan having an average molecular weight of 11,170 Da was used as the chitosan.
製造された口腔組成物の有効成分添加量による嗜好度調査は、実験に影響を及ぼしうる口腔疾患及びその他の疾患がなく、官能実験に基づいた訓練を受けた成人男女10人ずつを選別し、それぞれの口腔組成物を使用し、全体的な嗜好度を5点測定法で測定した。5点が一番良いことを意味し、1点は渋味が非常に強くて非常に良くないことを意味する。前記測定結果を下記表3に示す。 The preference survey based on the amount of active ingredient added to the manufactured oral composition selects 10 adult males and females who have undergone training based on sensory experiments without oral diseases and other diseases that may affect the experiment, Using each oral composition, overall palatability was measured using a 5-point scale. A score of 5 means the best, and a score of 1 means that the astringent taste is very strong and not very good. The measurement results are shown in Table 3 below.
前記表3に示すように、緑茶抽出物及びキトサンの含有量が増加する場合、渋味が強くなって全体的な嗜好度が低下することが確認され、特に、一定水準の含有量を超える場合は、強い渋味によって嗜好度が著しく減少することを確認した。前記結果により、緑茶抽出物の場合、1.5%以上添加される場合(カテキン含有量基準で0.3%(w/w))は、非常に強い渋味によって使用が難しいと判断され、緑茶抽出物が1.0%以下添加される場合(カテキン含有量基準で0.2%(w/w))は、一定水準以上の嗜好度を確保できて、緑茶抽出物は1.0%以下の使用が求められると評価された。 As shown in Table 3, when the content of green tea extract and chitosan increases, the astringent taste becomes stronger and the overall palatability decreases, especially when the content exceeds a certain level. confirmed that strong astringency significantly reduces palatability. Based on the above results, in the case of green tea extract, when it is added at 1.5% or more (0.3% (w/w) based on catechin content), it is judged that it is difficult to use due to its very strong astringency. When 1.0% or less of green tea extract is added (0.2% (w/w) based on catechin content), a certain level or more of palatability can be secured, and green tea extract is 1.0%. The use of the following was assessed as required.
また、キトサンの場合、0.15%以上添加される場合は、非常に強い渋味によって使用が難しいと判断され、0.1%以上添加される場合でも製品として販売されて使用されることが制限的であると判断され、キトサンが0.05%以下添加される場合は、一定水準以上の嗜好度を確保できて、キトサンは0.05%以下の使用が求められると評価された。 In the case of chitosan, if it is added in an amount of 0.15% or more, it is judged to be difficult to use due to its very strong astringency. It was judged to be restrictive, and when chitosan was added in an amount of 0.05% or less, a certain level or more of palatability could be ensured, and chitosan was evaluated to be required to be used in an amount of 0.05% or less.
実験例1-2.キトサン分子量による口臭制御効果の確認 Experimental example 1-2. Confirmation of halitosis control effect by chitosan molecular weight
前記実験例1-1で確認された添加量を基準にして、各有効成分の口臭制御効果を確認した。まず、キトサン分子量による口臭制御効果を下記表4の口腔組成物を用いて確認した。 Based on the addition amount confirmed in Experimental Example 1-1, the bad breath control effect of each active ingredient was confirmed. First, the oral cavity composition shown in Table 4 below was used to confirm the halitosis control effect of chitosan molecular weight.
前記製造された口腔組成物の口臭制御効果を確認するために、実験に影響を及ぼしうる口腔疾患及びその他の疾患のない成人男女10人ずつを選別し、口臭変化の有無を確認した。具体的には、前記実験群が2時間ごとに、口腔組成物の使用前と口腔組成物12mLを使用して30秒間うがいを行った後1時間が経過した時点で、口臭測定器(Oral Chroma CHM-2、韓国)を用いて図1と同様に、口臭原因物質(硫化水素(H2S)、メチルメルカプタン(CH3SH)、ジメチルスルフィド((CH3)2S)を用いて口臭値を測定し、その結果を下記表5~表7に示す。下記表5~表7での減少率は、使用前と比べた使用後の口臭成分の含有量が減少した程度を示す。 In order to confirm the halitosis control effect of the prepared oral composition, 10 adult males and females without oral diseases and other diseases that could affect the experiment were selected to check for changes in halitosis. Specifically, every 2 hours, the experimental group used a halitosis meter (Oral Chroma CHM-2, South Korea) was used to measure halitosis values using the halitosis-causing substances (hydrogen sulfide (H 2 S), methyl mercaptan (CH 3 SH), dimethyl sulfide ((CH 3 ) 2 S)) in the same manner as in FIG. The results are shown in Tables 5 to 7. The reduction rate in Tables 5 to 7 below indicates the extent to which the content of halitosis components after use compared to before use decreased.
前記表5~表7に示すように、キトサンを使用した場合、対照群に比べて口臭除去の効果を確認したものの、キトサンの平均分子量によって口臭除去の効果が異なることが確認された。特に、最も効果が良いことが確認された11,170Daの場合は、815Daに比べて抑制効果が約175%以上改善され、108,210Daに比べても約46%以上改善されることが確認され、対照群に比べては約9倍近く改善されることが確認された。従って、口腔洗浄のためにキトサンを使用するためには、平均分子量が11,170Daであるキトサンを使用することが最も好ましいことが確認された。 As shown in Tables 5 to 7, when chitosan was used, the effect of removing bad breath was confirmed compared to the control group, but it was confirmed that the effect of removing bad breath was different depending on the average molecular weight of chitosan. In particular, in the case of 11,170 Da, which was confirmed to be the most effective, the suppression effect was improved by about 175% or more compared to 815 Da, and it was confirmed that it was improved by about 46% or more compared to 108,210 Da. , was confirmed to be improved nearly 9 times compared to the control group. Therefore, it was confirmed that chitosan with an average molecular weight of 11,170 Da is most preferable for using chitosan for mouthwash.
実験例1-3.キトサン分子量による口臭制御効果の確認 Experimental example 1-3. Confirmation of halitosis control effect by chitosan molecular weight
前記実験例1-2と同様に、緑茶抽出物の量による口臭制御効果を下記表8の口腔組成物を用いて確認した。 In the same manner as in Experimental Example 1-2, the oral cavity composition shown in Table 8 below was used to confirm the effect of controlling bad breath depending on the amount of green tea extract.
前記製造された口腔組成物の口臭制御効果を確認するために、実験に影響を及ぼしうる口腔疾患及びその他の疾患のない成人男女10人ずつを選別し、前記実験例1-2のように口臭変化の有無を確認し、結果を下記表9~表11に示す。下記表9~表11での減少率は、使用前と比べた使用後の口臭成分の含有量が減少した程度を示す。 In order to confirm the halitosis control effect of the prepared oral composition, 10 adult males and females without oral diseases and other diseases that may affect the experiment were selected and treated as in Experimental Example 1-2. The presence or absence of change was confirmed, and the results are shown in Tables 9 to 11 below. The reduction rate in Tables 9 to 11 below indicates the degree of reduction in the content of halitosis components after use compared to before use.
前記表9~表11に示すように、緑茶抽出物を使用した場合、対照群に比べて口臭除去効果が改善され、使用量が増加するにつれて口臭除去効果は改善されたものの、0.5%添加した場合と1.0%添加した場合はその差が制限的であり、むしろ0.5%添加した場合の方が口臭除去効果により優れていることが確認された。特に、最も効果が良いことが確認された0.5%とは異なり、1.0%で前記実験例1-1及び表3に記載されたように、嗜好度も急激に減少することが確認され、口腔組成物に含まれる緑茶抽出物の含有量は、0.5%(w/w)であるものが最も好ましいことが確認された。 As shown in Tables 9 to 11, when the green tea extract was used, the effect of removing halitosis was improved compared to the control group. The difference between the addition and the addition of 1.0% is limited, and it was confirmed that the addition of 0.5% is more effective in removing bad breath. In particular, unlike 0.5%, which was confirmed to be the most effective, it was confirmed that the degree of preference decreased sharply at 1.0%, as described in Experimental Example 1-1 and Table 3. It was confirmed that the content of green tea extract contained in the oral cavity composition is most preferably 0.5% (w/w).
実験例1-4.緑茶抽出物とキトサン分子量による口臭制御効果の確認 Experimental example 1-4. Confirmation of halitosis control effect by green tea extract and chitosan molecular weight
前記実験例1-2及び実験例1-3で確認された結果に基づいて緑茶抽出物及びキトサンを併用した場合、口臭制御効果を確認した。口臭制御効果を下記表12の口腔組成物を用いて確認した。 Based on the results obtained in Experimental Examples 1-2 and 1-3, the combined use of green tea extract and chitosan was confirmed to be effective in controlling halitosis. Halitosis control effects were confirmed using the oral compositions shown in Table 12 below.
前記製造された口腔組成物の口臭制御効果を確認するために、実験に影響を及ぼしうる口腔疾患及びその他の疾患のない成人男女10人ずつを選別し、前記実験例1-2及び1-3のように口臭変化の有無を確認し、結果を下記表13~表15に示す。下記表13~表15での減少率は、使用前と比べた使用後の口臭成分の含有量が減少した程度を示す。 In order to confirm the halitosis control effect of the oral cavity composition prepared above, 10 adult males and females without oral diseases and other diseases that could affect the experiment were selected, and Experimental Examples 1-2 and 1-3 were selected. The presence or absence of change in bad breath was confirmed as described above, and the results are shown in Tables 13 to 15 below. The reduction rate in Tables 13 to 15 below indicates the degree of reduction in the content of halitosis components after use compared to before use.
前記表13~表15に示すように、緑茶抽出物とキトサンを併用した場合、全般的に口臭除去効果が著しく改善されたが、キトサン分子量による傾向性は、緑茶抽出物を使用しなかった実験例1-2と同様の傾向を示して、緑茶抽出物がキトサン分子量による口臭除去効果に影響を及ぼすものではないことが確認された。具体的に、最も効果が良いことが確認された11,170Daの場合は、815Daに比べて抑制効果が約58以上改善され、108,210Daに比べても約21%以上改善されることが確認され、対照群に比べては約8倍近く改善されることが確認された。従って、口腔洗浄のためにキトサンを使用するためには、緑茶抽出物と併用する場合でも、平均分子量が11,170Daであるキトサンを使用するのが最も好ましいことが確認された。 As shown in Tables 13 to 15 above, when green tea extract and chitosan were used in combination, the effect of removing bad breath was significantly improved in general, but the tendency according to the molecular weight of chitosan was not observed in experiments without green tea extract. It was confirmed that the green tea extract showed the same tendency as in Example 1-2 and did not affect the effect of removing halitosis due to chitosan molecular weight. Specifically, in the case of 11,170 Da, which was confirmed to be the most effective, the suppression effect was improved by about 58 or more compared to 815 Da, and it was confirmed that it was improved by about 21% or more compared to 108,210 Da. It was confirmed that it was improved by about 8 times compared to the control group. Therefore, it was confirmed that chitosan with an average molecular weight of 11,170 Da is most preferable for using chitosan for mouthwash, even when used in combination with green tea extract.
実験例1-5.緑茶抽出物とキトサンによるタンパク質老廃物除去効果の確認 Experimental example 1-5. Confirmation of protein waste removal effect by green tea extract and chitosan
前記実験例1-2~実験例1-4で確認された結果に基づいて、緑茶抽出物0.5%及び平均分子量が11,170Daであるキトサン0.05%を使用した口腔組成物を用いて30秒間うがいを行った後、口腔内のタンパク質分解副産物、すなわちタンパク質老廃物の除去効果を確認した。前記口腔内のタンパク質分解副産物の吸着排出の確認のために、キャラメル色素を口腔洗浄剤に溶解させて、吸着された副産物が茶色のキャラメル色素に染まってうがいの後吐き出した時、茶色の副産物としてタンパク質の分解副産物を確認した。前記実験結果を図2に示す。 Based on the results confirmed in Experimental Examples 1-2 to 1-4, an oral composition containing 0.5% green tea extract and 0.05% chitosan having an average molecular weight of 11,170 Da was used. After gargling for 30 seconds, the effect of removing proteolytic by-products in the oral cavity, ie protein waste products, was confirmed. In order to confirm the adsorption and discharge of the proteolytic by-products in the oral cavity, the caramel pigment was dissolved in a mouthwash. Protein degradation by-products were identified. The experimental results are shown in FIG.
前記図2に示すように、緑茶抽出物0.5%及び平均分子量が11,170Daであるキトサン0.05%を使用した口腔組成物を用いて30秒間うがいをした後吐き出した場合、使用前に比べて著しく多くの口腔内のタンパク質分解副産物が除去されることが確認された。 As shown in FIG. 2, when an oral composition containing 0.5% of green tea extract and 0.05% of chitosan having an average molecular weight of 11,170 Da was used, gargling for 30 seconds and then spitting out It was confirmed that significantly more proteolytic by-products in the oral cavity were removed compared to
前記の結果から、本発明の口腔組成物は、口腔内のタンパク質分解副産物を除去して口臭を効果的に制御できることが確認された。 From the above results, it was confirmed that the oral composition of the present invention can effectively control halitosis by removing proteolysis by-products in the oral cavity.
以上、本発明は一実施例を参考にして説明されたが、これは例示的なものに過ぎず、当該技術分野における通常の知識を有する者であれば、ここから様々な変形及び均等な実施例が可能であることを理解できるだろう。 Although the present invention has been described with reference to one embodiment, this is merely an example and a person of ordinary skill in the art will appreciate various modifications and equivalent implementations thereof. It will be appreciated that examples are possible.
本発明は、天然物であるキトサンと緑茶抽出物を主成分として使用するものであるため、人体に有害な合成化合物の使用を最小限に抑えることができるので安全であるだけでなく、口臭除去効果に優れながらも渋味など使用する上で不便さを感じさせることなく嗜好度に優れて、消費者の使用感及び満足感を向上させる効果を有するので、様々な用途の口臭改善用口腔組成物として使用することができる。 Since the present invention uses chitosan and green tea extract, which are natural products, as main ingredients, the use of synthetic compounds that are harmful to the human body can be minimized. Although it is highly effective, it does not cause inconvenience such as astringent taste when used, and has an excellent degree of palatability, and has the effect of improving the feeling of use and satisfaction of consumers. can be used as an object.
Claims (4)
前記キトサンは、重量平均分子量(Mw)が10,000Da~57,000Daであることを特徴とする口臭改善用口腔組成物。 An oral composition for improving bad breath containing chitosan and green tea extract as active ingredients,
An oral cavity composition for improving bad breath, wherein the chitosan has a weight average molecular weight (Mw) of 10,000 Da to 57,000 Da.
前記緑茶抽出物の含有量は、前記緑茶抽出物に含まれているカテキンの含有量を基準にして、前記口臭改善用口腔組成物100重量部を基準にして、前記カテキンの含有量が0.1~0.2であることを特徴とする、請求項1に記載の口臭改善用組成物。 The green tea extract may contain catechins,
The content of the green tea extract is based on the content of catechins contained in the green tea extract, and based on 100 parts by weight of the oral cavity composition for improving bad breath, the content of the catechins is 0.5 parts by weight. The composition for improving bad breath according to claim 1, wherein the ratio is 1 to 0.2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2020-0143990 | 2020-10-31 | ||
| KR1020200143990A KR102373373B1 (en) | 2020-10-31 | 2020-10-31 | Oral composition for preventing halitosis |
| PCT/KR2021/011533 WO2022092522A1 (en) | 2020-10-31 | 2021-08-27 | Oral composition for ameliorating bad breath |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023533273A true JP2023533273A (en) | 2023-08-02 |
| JP7541780B2 JP7541780B2 (en) | 2024-08-29 |
Family
ID=80814315
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023500348A Active JP7541780B2 (en) | 2020-10-31 | 2021-08-27 | Oral composition for improving bad breath |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP7541780B2 (en) |
| KR (1) | KR102373373B1 (en) |
| WO (1) | WO2022092522A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114948812A (en) * | 2022-05-30 | 2022-08-30 | 中山市多美化工有限公司 | Oral care solution containing halitosis-removing and bacteriostatic composition |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0121550B1 (en) | 1993-05-25 | 1997-11-27 | 장영신 | Oral Composition |
| KR100327886B1 (en) | 1994-06-29 | 2002-08-01 | 라이온 가부시키가이샤 | Oral composition |
| KR100450389B1 (en) * | 1995-11-25 | 2006-04-17 | 주식회사 엘지생활건강 | Oral liquid composition for removing bad breath |
| KR20020028765A (en) * | 2001-07-25 | 2002-04-17 | 송병식 | Tooth paste composition against paradental desease comprising chitosan and oriental herb medicine extracts |
| JP2005154339A (en) | 2003-11-26 | 2005-06-16 | Morinaga & Co Ltd | Bad breath reduction composition |
| KR100805635B1 (en) * | 2006-07-06 | 2008-02-20 | 주식회사 엘지생활건강 | Phase transition bad breath remover with enhanced stability |
| JP2009091322A (en) | 2007-10-11 | 2009-04-30 | Kao Corp | Antibacterial composition |
| KR101157088B1 (en) | 2011-06-17 | 2012-06-21 | 백설옥 | The oral composite that consist with Hardy Orange as mainly and the producing method thereof |
| KR20130116486A (en) | 2012-04-05 | 2013-10-24 | (주)아모레퍼시픽 | Oral composition for inhibiting dental plaque |
| KR20140055885A (en) * | 2012-11-01 | 2014-05-09 | (주) 바이오에스텍 | The gargle composites for the increment of the oral care |
| JP3193018U (en) * | 2014-07-01 | 2014-09-11 | 株式会社えがお | Deodorant composition tablets |
| JP2016074723A (en) * | 2015-12-03 | 2016-05-12 | ガバ・インターナショナル・ホールディング・アクチェンゲゼルシャフト | Mouthrinse composition |
| KR101790034B1 (en) | 2016-08-22 | 2017-10-25 | 강원대학교산학협력단 | Oral composition for preventing cavity and halitosis |
| KR20200034570A (en) * | 2018-09-21 | 2020-03-31 | 주식회사 엘지생활건강 | Composition for Removing Halitosis |
-
2020
- 2020-10-31 KR KR1020200143990A patent/KR102373373B1/en active Active
-
2021
- 2021-08-27 JP JP2023500348A patent/JP7541780B2/en active Active
- 2021-08-27 WO PCT/KR2021/011533 patent/WO2022092522A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022092522A1 (en) | 2022-05-05 |
| KR102373373B1 (en) | 2022-03-11 |
| JP7541780B2 (en) | 2024-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006320846B2 (en) | Vehicles for oral care with Magnolia Bark Extract | |
| CN102573770B (en) | Isopropyl methyl phenol-containing liquid composition for oral cavity | |
| CN102548526B (en) | Dentifrice composition | |
| JP4246736B2 (en) | Composition for oral dental treatment of medicinal herbs and preparation method thereof | |
| JP5825532B2 (en) | Tobacco tar remover and compositions based thereon | |
| KR20130107397A (en) | A composition of a bubble dentifrice and the method of making it | |
| ES2373734T3 (en) | ORAL COMPOSITIONS CONTAINING OXIDIZED CAMELIA. | |
| KR20230153847A (en) | Antibacterial toothpaste composition with excellent effect of preventing gum disease and removing bad breath | |
| KR102221423B1 (en) | Composition for inhibiting halitosis and enhancing oral hygiene | |
| JP7541780B2 (en) | Oral composition for improving bad breath | |
| KR102638091B1 (en) | Toothpaste composition with whitening function | |
| KR101632910B1 (en) | Mouth spray composition comprising cypress extracts and medical herb extracts and manufacturing method thereof | |
| KR101881636B1 (en) | Composition for prevention or treatment of oral disease comprising Pueraria Extract | |
| KR101703269B1 (en) | Oral care composition comprising Magnolia officinalis extract and bicarbonate | |
| JP7108304B2 (en) | Liquid oral composition | |
| KR20180048041A (en) | Oral Cleaning Composition and Oral Products Using Thereof | |
| Patil et al. | Review on Herbal Toothpowder | |
| KR20140055885A (en) | The gargle composites for the increment of the oral care | |
| KR102704053B1 (en) | Manufacturing method of toothpaste composition including ingredient of improving oral dryness | |
| KR101344803B1 (en) | Oral care composition comprising extract of machilus thunbergii and sequestering agent | |
| KR101287800B1 (en) | Oral composition | |
| KR20170120411A (en) | Composition for prevention or treatment of oral disease comprising Scopoletin | |
| KR20170120399A (en) | Composition for prevention or treatment of oral disease comprising Genistein | |
| KR101818211B1 (en) | Composition for prevention or treatment of oral disease comprising Arctill fructus Extract | |
| KR20170103482A (en) | Composition for prevention or treatment of oral disease comprising Glechoma hederacea extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230105 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240130 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240430 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240628 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240716 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240809 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7541780 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |